Wai‐Kay Seto - Concepedia

Author

Wai‐Kay Seto

Also Known As

Cong, Lou, D. But, Masato Furuhashi, Seto, Wai-Kay, W K Seto, W K Walter Seto, W. K. Seto, W. Seto, W.-K Seto, W.-K. Seto

455

Publications

12.2K

Citations

H-Index

106

Concepts

All Affiliations

University of Hong Kong Queen Mary Hospital Chinese University of Hong Kong University of Hong Kong - Shenzhen Hospital Erasmus MC

About

Wai‐Kay Seto is an author at University of Hong Kong specializing in medicine, hepatitis, and viral hepatitis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	46	2.7K
2	Public Health	9	9	291
3	Health Sciences	5	5	275
4	Natural Sciences	2	2	312
5	Allergy	1	1	12

Wai‐Kay Seto

164

Publications

8.6K

Citations

H-Index

Page 1

	Year	Citations
Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score Hwai‐I Yang, Man‐Fung Yuen, Henry Lik‐Yuen Chan, The Lancet Oncology Hepatitis DEpidemiologyHepatologyViral HepatitisMedicine	2011	649
Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study Wai‐Kay Seto, Thomas S. Y. Chan, Yu‐Yan Hwang, Journal of Clinical Oncology	2014	319
Long-Term Lamivudine Therapy Reduces the Risk of Long-Term Complications of Chronic Hepatitis B Infection even in Patients without Advanced Disease Man‐Fung Yuen, Wai‐Kay Seto, Danny Hoi-Fan Chow, Antiviral Therapy	2007	254
Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study Wai‐Kay Seto, Aric J. Hui, Vincent Wai‐Sun Wong, Gut	2014	209
Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study) Grishma Hirode, Hannah Choi, Chien‐Hung Chen, Gastroenterology Ide Analogue WithdrawalHepatologyViral HepatitisOff-therapy ResponseHepatitis	2021	177
Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B Ching‐Lung Lai, Danny Wong, Philip P.C. Ip, Journal of Hepatology Ide Analogue TreatmentHepatologyViral HepatitisLong-term NucleosNatural Sciences	2016	174
Hepatitis B virus core‐related antigen as a surrogate marker for covalently closed circular DNA Danny Ka‐Ho Wong, Wai‐Kay Seto, Ka Shing Cheung, Liver International	2016	169
Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety Man‐Fung Yuen, Wai‐Kay Seto, James Fung, The American Journal of Gastroenterology	2011	163
Modelling NAFLD disease burden in four Asian regions—2019‐2030 Chris Estes, Henry Lik‐Yuen Chan, Rong‐Nan Chien, Alimentary Pharmacology & Therapeutics	2020	150
Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency Danny Ka‐Ho Wong, Wai‐Kay Seto, James Fung, Clinical Gastroenterology and Hepatology Circular DnaIde AnaloguesDifferent PotencyViral HepatitisNatural Sciences	2013	138

Page 1